Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer
Standard
Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. / Gandaglia, Giorgio; Sun, Maxine; Hu, Jim C; Novara, Giacomo; Choueiri, Toni K; Nguyen, Paul L; Schiffmann, Jonas; Graefen, Markus; Shariat, Shahrokh F; Abdollah, Firas; Briganti, Alberto; Montorsi, Francesco; Trinh, Quoc-Dien; Karakiewicz, Pierre I.
In: EUR UROL, Vol. 66, No. 6, 01.12.2014, p. 1125-1132.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer
AU - Gandaglia, Giorgio
AU - Sun, Maxine
AU - Hu, Jim C
AU - Novara, Giacomo
AU - Choueiri, Toni K
AU - Nguyen, Paul L
AU - Schiffmann, Jonas
AU - Graefen, Markus
AU - Shariat, Shahrokh F
AU - Abdollah, Firas
AU - Briganti, Alberto
AU - Montorsi, Francesco
AU - Trinh, Quoc-Dien
AU - Karakiewicz, Pierre I
N1 - Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.
PY - 2014/12/1
Y1 - 2014/12/1
N2 - BACKGROUND: Androgen deprivation therapy (ADT) might increase the risk of acute kidney injury (AKI) in patients with prostate cancer (PCa).OBJECTIVE: To examine the impact of ADT on AKI in a large contemporary cohort of patients with nonmetastatic PCa representing the US population.DESIGN, SETTING, AND PARTICIPANTS: Overall, 69 292 patients diagnosed with nonmetastatic PCa between 1995 and 2009 were abstracted from the Surveillance Epidemiology and End Results-Medicare database.OUTCOMES MEASUREMENTS AND STATISTICAL ANALYSES: Patient in both treatment arms (ADT vs. no ADT) were matched using propensity-score methodology. Ten-year AKI rates were estimated. Competing-risks regression analyses tested the association between ADT and AKI, after adjusting for the risk of death during follow-up.RESULTS AND LIMITATIONS: Overall, the 10-yr AKI rates were 24.9% versus 30.7% for ADT-naive patients versus those treated with ADT, respectively (p<0.001). When patients were stratified according to the type of ADT, the 10-yr AKI rates were 31.1% versus 26.0% for men treated with gonadotropin-releasing hormone (GnRH) agonists and bilateral orchiectomy, respectively (p<0.001). In multivariable analyses, the administration of GnRH agonists (hazard ratio [HR]: 1.24; 95% confidence interval [CI], 1.18-1.31; p<0.001), but not bilateral orchiectomy (HR: 1.11; 95% CI, 0.96-1.29; p=0.1), was associated with the risk of experiencing AKI. Our study is limited by its retrospective design.CONCLUSIONS: ADT is associated with an increased risk of AKI in patients with nonmetastatic PCa. In particular, the administration of GnRH agonists, but not surgical castration, may substantially increase the risk of experiencing AKI. These observations should help provide physicians with better patient selection to reduce the risk of AKI.PATIENT SUMMARY: The administration of gonadotropin-releasing hormone agonists, but not bilateral orchiectomy, increases the risk of acute kidney injury (AKI) in patients with prostate cancer (PCa). These observations should help provide physicians with better patient selection to reduce the risk of AKI in PCa patients.
AB - BACKGROUND: Androgen deprivation therapy (ADT) might increase the risk of acute kidney injury (AKI) in patients with prostate cancer (PCa).OBJECTIVE: To examine the impact of ADT on AKI in a large contemporary cohort of patients with nonmetastatic PCa representing the US population.DESIGN, SETTING, AND PARTICIPANTS: Overall, 69 292 patients diagnosed with nonmetastatic PCa between 1995 and 2009 were abstracted from the Surveillance Epidemiology and End Results-Medicare database.OUTCOMES MEASUREMENTS AND STATISTICAL ANALYSES: Patient in both treatment arms (ADT vs. no ADT) were matched using propensity-score methodology. Ten-year AKI rates were estimated. Competing-risks regression analyses tested the association between ADT and AKI, after adjusting for the risk of death during follow-up.RESULTS AND LIMITATIONS: Overall, the 10-yr AKI rates were 24.9% versus 30.7% for ADT-naive patients versus those treated with ADT, respectively (p<0.001). When patients were stratified according to the type of ADT, the 10-yr AKI rates were 31.1% versus 26.0% for men treated with gonadotropin-releasing hormone (GnRH) agonists and bilateral orchiectomy, respectively (p<0.001). In multivariable analyses, the administration of GnRH agonists (hazard ratio [HR]: 1.24; 95% confidence interval [CI], 1.18-1.31; p<0.001), but not bilateral orchiectomy (HR: 1.11; 95% CI, 0.96-1.29; p=0.1), was associated with the risk of experiencing AKI. Our study is limited by its retrospective design.CONCLUSIONS: ADT is associated with an increased risk of AKI in patients with nonmetastatic PCa. In particular, the administration of GnRH agonists, but not surgical castration, may substantially increase the risk of experiencing AKI. These observations should help provide physicians with better patient selection to reduce the risk of AKI.PATIENT SUMMARY: The administration of gonadotropin-releasing hormone agonists, but not bilateral orchiectomy, increases the risk of acute kidney injury (AKI) in patients with prostate cancer (PCa). These observations should help provide physicians with better patient selection to reduce the risk of AKI in PCa patients.
U2 - 10.1016/j.eururo.2014.01.026
DO - 10.1016/j.eururo.2014.01.026
M3 - SCORING: Journal article
C2 - 24495466
VL - 66
SP - 1125
EP - 1132
JO - EUR UROL
JF - EUR UROL
SN - 0302-2838
IS - 6
ER -
